Cardiol Therapeutics (TSE: CRDL- OTCQX: CRTPF) President and CEO David Elsley joined Steve Darling from Proactive Vancouver with news the company has initiated their Health Canada approved Phase 1 clinical study of CardiolRx.
Elsley telling Proactive the study will be a double-blind, placebo-controlled, randomized study to assess safety, tolerability, and pharmacokinetics of single and multiple day doses of CardiolRx.
Price: 3.4 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Cardiol Therapeutics (TSE: CRDL-OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive with news the company has selected a contract research organization to conduct their Phase II/III trial studying the effectiveness of CardiolRx in COVID-19 patients. Elsley telling Proactive why...
Prev article
